Radiating Positivity: Roche’s Actemra Sees More Positive Results In Third Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing positive results from its RADIATE study, Roche awaits monotherapy study results to determine whether to file as first-line treatment, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Roche Files BLA For Rheumatoid Arthritis Therapy Actemra
The novel interleukin-6 receptor-inhibiting mAb has a projected September 2008 action date.
Roche Files BLA For Rheumatoid Arthritis Therapy Actemra
The novel interleukin-6 receptor-inhibiting mAb has a projected September 2008 action date.
Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis
Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.